Diagnostic Value of Serum Levels of IL-22, IL-23, and IL-17 for Idiopathic Pulmonary Fibrosis Associated with Lung Cancer

References

• Le Garrec M, Rousseau C, Thepault F, Kerjouan M, Sale A, Jouneau S. Prevalence, predicting factors and impact of internet use by patients with idiopathic pulmonary fibrosis: a cross-sectional observational study. Respir Med Res. 2021;79:100818. doi:10.1016/j.resmer.2021.100818
   PubMedGoogle Scholar
• Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476–486.
   PubMed Web of Science ®Google Scholar
• Biondini D, Cocconcelli E, Bernardinello N, et al. Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment. Respir Res. 2021;22(1):98. doi:10.1186/s12931-021-01694-z
   PubMed Web of Science ®Google Scholar
• Ghang B, Nam SH, Lee J, et al. Correction to: risk of progression of idiopathic pulmonary fibrosis to connective tissue disease: a long-term observational study in 527 patients. Clin Rheumatol. 2021;40(6):2525.
   PubMed Web of Science ®Google Scholar
• Rahaghi F, Belperio JA, Fitzgerald J, et al. Delphi consensus recommendations on management of dosing, adverse events, and comorbidities in the treatment of idiopathic pulmonary fibrosis with nintedanib, clinical medicine insights. Circ Respir Pulm Med. 2021;15:11795484211006050.
   Google Scholar
• Fedi A, Keddache S, Quetant S, et al. Concurrence of 1- and 3-min sit-to-stand tests with the 6-min walk test in idiopathic pulmonary fibrosis. Respiration. 2021;100:1–9.
   PubMed Web of Science ®Google Scholar
• Kai Y, Matsuda M, Fukuoka A, et al. Remarkable response of non-small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis. Thorac Cancer. 2021;12(9):1457–1460. doi:10.1111/1759-7714.13935
   PubMed Web of Science ®Google Scholar
• Hata A, Nakajima T, Matsusaka K, et al. Genetic alterations in squamous cell lung cancer associated with idiopathic pulmonary fibrosis. J Clin Investig. 2021;148(12):3008–3018. doi:10.1002/ijc.33499
   Web of Science ®Google Scholar
• Song MJ, Kim SY, Park MS, Kang MJ, Lee SH, Park SC. A nationwide population-based study of incidence and mortality of lung cancer in idiopathic pulmonary fibrosis. Sci Rep. 2021;11(1):2596. doi:10.1038/s41598-021-82182-8
   PubMed Web of Science ®Google Scholar
• Kanaji N, Shimizu J, Sakai K, et al. Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy. Ther Adv Respir Dis. 2020;14:1753466620963866. doi:10.1177/1753466620963866
   Web of Science ®Google Scholar
• Leng D, Yi J, Xiang M, Zhao H, Zhang Y. Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling. BMC Cancer. 2020;20(1):986. doi:10.1186/s12885-020-07494-w
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Yano Y, Kuge T, et al. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: a retrospective cohort study. Thorac Cancer. 2020;11(11):3317–3325. doi:10.1111/1759-7714.13675
   PubMed Web of Science ®Google Scholar
• Behram M, Oglak SC, Baskiran Y, et al. Maternal serum IL-22 concentrations are significantly upregulated in patients with preterm premature rupture of membranes. Ginekol Pol. 2021. doi:10.5603/GP.a2021.0036
   Web of Science ®Google Scholar
• Nehmar R, Fauconnier L, Alves-Filho J, et al. Aryl hydrocarbon receptor(Ahr)-dependent Il-22 expression by type 3 innate lymphoid cells control of acute joint inflammation. J Cell Mol Med. 2021;25(10):4721–4731. doi:10.1111/jcmm.16433
   PubMed Web of Science ®Google Scholar
• Walker EM, Slisarenko N, Gerrets GL, et al. Dysregulation of IL-17/IL-22 Effector functions in blood and gut mucosal gamma delta T cells correlates with increase in circulating leaky gut and inflammatory markers during cART-treated chronic SIV infection in macaques. Front Immunol. 2021;12:647398. doi:10.3389/fimmu.2021.647398
   PubMed Web of Science ®Google Scholar
• Duchemann B, Pluvy J, Crestani B, Zalcman G, Nunes H. Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. Eur J Cancer. 2021;145:179–182. doi:10.1016/j.ejca.2020.12.016
   PubMed Web of Science ®Google Scholar
• Lee HY, Lee J, Lee CH, Han K, Choi SM. Risk of cancer incidence in patients with idiopathic pulmonary fibrosis: a nationwide cohort study. Respirology. 2021;26(2):180–187. doi:10.1111/resp.13911
   PubMed Web of Science ®Google Scholar
• Otsubo K, Iwama E, Ijichi K, et al. Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis. Cancer Sci. 2020;111(7):2482–2487. doi:10.1111/cas.14488
   PubMed Web of Science ®Google Scholar
• Shiratori T, Tanaka H, Tabe C, et al. Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: a case report and literature review. Thorac Cancer. 2020;11(6):1720–1723. doi:10.1111/1759-7714.13437
   PubMed Web of Science ®Google Scholar
• Rubio K, Castillo-Negrete R, Barreto G. Non-coding RNAs and nuclear architecture during epithelial-mesenchymal transition in lung cancer and idiopathic pulmonary fibrosis. Cell Signal. 2020;70:109593. doi:10.1016/j.cellsig.2020.109593
   PubMed Web of Science ®Google Scholar
• Iida Y, Gon Y, Nakanishi Y, et al. Genomic analysis between idiopathic pulmonary fibrosis and associated lung cancer using laser-assisted microdissection: a case report. Thorac Cancer. 2021;12(9):1449–1452. doi:10.1111/1759-7714.13924
   PubMed Web of Science ®Google Scholar
• Lin X, Tawch S, Wong HT, et al. Nrf2 through aryl hydrocarbon receptor regulates IL-22 response in CD4(+) T cells. J Immunol. 2021;206(7):1540–1548. doi:10.4049/jimmunol.1900656
   PubMed Web of Science ®Google Scholar
• Dubenko OE, Chyniak OS, Potapov OO. Levels of proinflammatory cytokines Il-17 and Il-23 in patients with Alzheimer’s disease, mild cognitive impairment and vascular dementia. Wiad Lek. 2021;74(1):68–71. doi:10.36740/WLek202101113
   PubMedGoogle Scholar
• Ogongo P, Tezera LB, Ardain A, et al. Tissue resident-like CD4+ T cells secreting IL-17 control Mycobacterium tuberculosis in the human lung. J Clin Invest. 2021;131(10). doi:10.1172/JCI142014
   PubMed Web of Science ®Google Scholar
• Bi Y, Cao J, Jin S, et al. Interleukin-22 promotes lung cancer cell proliferation and migration via the IL-22R1/STAT3 and IL-22R1/AKT signaling pathways. Mol Cell Biochem. 2016;415(1–2):1–11. doi:10.1007/s11010-016-2663-8
   PubMed Web of Science ®Google Scholar
• Tufman A, Huber RM, Volk S, et al. Interleukin-22 is elevated in lavage from patients with lung cancer and other pulmonary diseases. BMC Cancer. 2016;16(1):409. doi:10.1186/s12885-016-2471-2
   PubMed Web of Science ®Google Scholar
• Baird AM, Leonard J, Naicker KM, Kilmartin L, O’Byrne KJ, Gray SG. IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. Lung Cancer. 2013;79(1):83–90. doi:10.1016/j.lungcan.2012.10.003
   PubMed Web of Science ®Google Scholar
• Li J, Zhang L, Zhang J, et al. Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor. Carcinogenesis. 2013;34(3):658–666. doi:10.1093/carcin/bgs384
   PubMed Web of Science ®Google Scholar
• Bujang MA. A step-by-step process on sample size determination for medical research. Malays J Med Sci. 2021;28(2):15–27.
   PubMed Web of Science ®Google Scholar